Gastroparesis Treatment - Global Strategic Business Report

The global market for Gastroparesis Treatment was valued at US$6.4 Billion in 2025 and is projected to reach US$8.3 Billion by 2032, growing at a CAGR of 3.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Gastroparesis Treatment Market - Key Trends & Drivers Summarized

Why Is Gastroparesis Treatment Gaining Attention in the Gastroenterology Field?

Gastroparesis, a condition in which the stomach muscles are unable to move food through the digestive tract properly, is becoming an increasingly important focus in gastroenterology due to its growing prevalence and significant impact on patients' quality of life. This disorder, which often results from underlying conditions such as diabetes, can lead to symptoms like nausea, vomiting, bloating, early satiety, and severe abdominal discomfort. As the incidence of diabetes rises globally, the number of gastroparesis cases linked to diabetic neuropathy has also increased, making it a major concern in managing chronic conditions. The complexity of gastroparesis, with its multi-faceted causes and the variability of its symptoms, has made treatment a significant challenge. Patients often struggle with long-term management strategies, leading to high levels of frustration, reduced productivity, and an overall diminished quality of life. Additionally, gastroparesis frequently results in nutritional deficiencies and weight loss, making it not only a gastrointestinal issue but also a significant metabolic concern. Consequently, there is an increasing demand for more effective treatments, including drug therapies, dietary changes, and technological interventions, to better manage the condition. The growing awareness of gastroparesis and its association with other chronic diseases has led to greater research efforts and investment into finding solutions, with the aim of improving symptom control and patient outcomes.

How Are Advancements in Gastroparesis Treatments Improving Patient Care?

Advancements in the treatment of gastroparesis have greatly improved the ability to manage this challenging condition and enhance patient care. Traditionally, gastroparesis management has involved a combination of dietary modifications, prokinetic drugs, and symptomatic treatments aimed at alleviating nausea and vomiting. However, recent developments have expanded the range of treatment options and improved the effectiveness of symptom management. One of the key advancements has been the introduction of new prokinetic drugs that stimulate gastric motility. Drugs such as metoclopramide, which was historically the mainstay of treatment, are now being complemented by newer options, such as the dopamine antagonists and 5-HT4 agonists, that have fewer side effects and are better tolerated by patients. Additionally, gastric electrical stimulation (GES) has emerged as a promising treatment for patients with refractory gastroparesis who do not respond to conventional therapies. This technique involves implanting a device that delivers electrical pulses to the stomach muscles, improving motility and alleviating symptoms like nausea and vomiting. Another breakthrough in treatment has been the use of intravenous therapies such as antiemetics and fluids to manage dehydration and nutritional deficiencies that are common in patients with severe gastroparesis. Furthermore, dietary management has also advanced with specialized nutritional interventions, including the use of liquid meal replacements and enteral feeding when necessary, ensuring that patients maintain adequate nutrition while managing the condition. These advancements, combined with improved diagnostic techniques such as gastric emptying scintigraphy, which helps in assessing the severity of the condition, are enabling more personalized and effective treatment plans for individuals suffering from gastroparesis.

What Are the Key Factors Driving the Growth of the Gastroparesis Treatment Market?

The growth of the gastroparesis treatment market is driven by several key factors, including the rising prevalence of diabetes, an aging population, and increasing awareness of the condition. Gastroparesis is often associated with diabetes, particularly long-term uncontrolled type 1 and type 2 diabetes, which leads to damage to the nerves that control stomach muscles. As the global diabetes epidemic continues to rise, so does the incidence of gastroparesis, creating a growing demand for effective treatments. Additionally, the aging population, with its higher prevalence of both diabetes and other chronic conditions that contribute to gastroparesis, is another key factor driving market growth. The increasing recognition of gastroparesis as a debilitating condition that significantly impacts quality of life has also contributed to the growing demand for treatments. Physicians and healthcare providers are becoming more aware of gastroparesis and its symptoms, leading to better diagnosis and an increased focus on managing the condition. This increased recognition, coupled with advances in diagnostic tools, is encouraging more patients to seek treatment. Furthermore, the development of more effective treatment options, including newer pharmacological agents, minimally invasive procedures, and non-invasive therapies, has helped address the unmet needs in gastroparesis management. Additionally, increased patient advocacy, with more support from organizations focused on raising awareness of gastroparesis and promoting research, has led to greater funding for clinical trials and research into better treatment options. Together, these factors are driving growth in the gastroparesis treatment market as more effective management strategies become available and awareness of the condition spreads.

What Are the Primary Drivers Behind the Growth of the Gastroparesis Treatment Market?

The growth of the gastroparesis treatment market is fueled by several key drivers related to the rising incidence of the condition, advancements in medical research, and the increased availability of innovative treatment options. As the number of individuals with diabetes continues to grow globally, gastroparesis is becoming more common, particularly in patients with long-standing, poorly controlled diabetes. This is creating a growing need for targeted treatments that can effectively manage the symptoms and improve gastric motility. Advances in medical research have also played a pivotal role in driving market growth. New drug formulations that specifically target the mechanisms behind gastroparesis, such as motility agents and antiemetics, are improving treatment outcomes and offering patients better symptom control. The development of gastric electrical stimulation therapy for refractory cases is another breakthrough that is helping to improve quality of life for patients who do not respond to conventional treatments. Furthermore, personalized medicine is becoming increasingly important in the treatment of gastroparesis, with more tailored treatment plans based on individual patient needs. The growth of patient-centered care and the focus on improving overall well-being, including nutritional support and lifestyle interventions, is also contributing to the expanding market. Additionally, the increasing recognition of gastroparesis by healthcare providers and patients, coupled with greater awareness efforts and patient advocacy, is driving demand for effective therapies. The market is also benefiting from the expanding availability of clinical trials and research, leading to the discovery of new treatments and a broader understanding of the condition. Together, these drivers are creating a favorable environment for the continued growth of the gastroparesis treatment market, improving the lives of patients and expanding therapeutic options.

Report Scope

The report analyzes the Gastroparesis Treatment market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Drug Class (Prokinetic Agents Drug Class, Antiemetic Drugs Drug Class, Proton Pump Inhibitors Drug Class, Other Drug Classes); Disease Indication (Diabetes Gastroparesis Disease Indication, Idiopathic Gastroparesis Disease Indication, Post-surgical Gastroparesis Disease Indication); Type (Over-the-Counter Drugs Type, Prescription Drugs Type)Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel); Administration Route (Oral Administration Route, Injectables Administration Route, Nasal Administration Route)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Prokinetic Agents Drug Class segment, which is expected to reach US$3.3 Billion by 2032 with a CAGR of a 5.0%. The Antiemetic Drugs Drug Class segment is also set to grow at 2.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2025, and China, forecasted to grow at an impressive 6.8% CAGR to reach $1.7 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Gastroparesis Treatment Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Gastroparesis Treatment Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Gastroparesis Treatment Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, AbbVie Inc., Alfa Wassermann S.p.A., AstraZeneca plc, Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Gastroparesis Treatment market report include:

• Abbott Laboratories
• AbbVie Inc.
• Alfa Wassermann S.p.A.
• AstraZeneca plc
• Bayer AG
• Boston Scientific Corp.
• Cardinal Health, Inc.
• Cipla Ltd.
• C.R. Bard, Inc.
• Enterra Medical, Inc.
• Evoke Pharma, Inc.
• Janssen Global Services
• Kimberly-Clark Corp.
• Medtronic plc
• Neurogastrx, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Co.
• Teva Pharmaceutical Ind.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.